Plexxikon Explained
Plexxikon is an American drug discovery company based in South San Francisco, California. It was co-founded in 2001 by Joseph Schlessinger of Yale University, and Sung-Hou Kim of the University of California, Berkeley.
It uses a proprietary structural biology-based platform called Scaffold-Based Drug Discovery to build a pipeline of products in multiple therapeutic areas. This discovery process integrates multiple technologies, including structural screening as one key component, that it hopes will give a significant competitive advantage over other approaches.[1]
In April 2011, Plexxikon was acquired by the Japanese pharmaceutical company Daiichi Sankyo for $805 million and an additional $130 million in potential milestone payments.[2] [3] [4]
Daiichi Sankyo announced the shutdown of Plexxikon in 2022.[5]
Drug pipeline
- Vemurafenib (Zelboraf) and pexidartinib (Turalio) are two FDA approved drugs developed by Plexxikon
- Plexxikon is collaborating with Wyeth Pharmaceuticals on several products for use in type II diabetes and other metabolic disorders.[6] The most advanced of these agents is indeglitazar (PLX204), which is currently in Phase II clinical trials for type 2 diabetes.[7]
- PLX7486 is a CSF1R antagonist and pan-TRK inhibitor in clinical trials for advanced solid tumors.[8] [9]
See also
Notes and References
- Web site: AI Drug Discovery: Key Trends and Developments in Pharmaceutical Industry . 2023-09-11 . www.biopharmatrend.com . en.
- Web site: Daiichi Sankyo to Acquire Plexxikon. 2011-02-28 . Plexxikon . https://web.archive.org/web/20110306091816/https://www.plexxikon.com/view.cfm/88/Press-Releases . 2011-03-06 . dead.
- Web site: 2011-03-03. Plexxikon acquired by Daiichi Sankyo. 2020-08-06. Haberman Associates. en-US.
- Web site: Daiichi Sankyo, Inc. Completes Plexxikon Inc. Acquisition. 2020-08-06. BioSpace. en-US.
- Web site: Madeline . Wells. 2022-01-12. South SF company bought for $800 million is being shut down. SFGATE. en-US . https://web.archive.org/web/20220112185128/https://www.sfgate.com/local/article/South-SF-Plexxikon-to-shut-down-16770179.php . 2022-01-12 . live.
- Web site: 28 October 2004. Wyeth, Plexxikon tie up to develop novel diabetes & metabolic disorders treatment. dead. https://web.archive.org/web/20071024140445/http://www.pharmabiz.com/article/detnews.asp?SecArch=&articleid=24409§ionid=14. 24 October 2007.
- 18 December 2007. Study Evaluating PPM-204 In Subjects With Type 2 Diabetes - Full Text View - ClinicalTrials.gov. 2020-10-09. Clinical Trials. en.
- Web site: Fms/Trk tyrosine kinase inhibitor PLX7486 . NCI Drug Dictionary . National Cancer Institute .
- 2018-08-02. Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors. live. https://web.archive.org/web/20211117224901/https://clinicaltrials.gov/ct2/show/NCT01804530. 2021-11-17. ClinicalTrials.gov.
